Sopharma AD reports sale of treasury shares worth BGN 1.87 million

Ognyan Ivanov Donev Chairman of the Board of Directors and Executive Director Sopharma AD
Ognyan Ivanov Donev Chairman of the Board of Directors and Executive Director - Sopharma AD
0Comments

Sopharma AD has announced the sale of 770,286 treasury shares on August 4, 2025. The transaction represents 0.14% of the company’s share capital and was completed at a total value of BGN 1,871,797.84 on the Bulgarian Stock Exchange. The average price per share in this sale was BGN 2.43.

Following this transaction, Sopharma AD holds a total of 25,269,914 treasury shares, which now represent 4.69% of its share capital.

The company stated: “According to the requirements of art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, ‘Sopharma’ AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on August 4, 2025 the Company sold 770 286 (seven hundred thousand two hundred eighty-six) repurchased own shares representing 0.14% of the share capital of the Company, at a total value of BGN 1 871 797.84 on the Bulgarian Stock Exchange, the average price per share was BGN 2.43.”

The notification is made in accordance with European Union regulations regarding market transparency and disclosure for listed companies.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.